

Retail Equity Research (South India Focus)

Coromandel International Ltd

Fertilizers

BSE CODE : 506395NSE CODE: COROMANDELBLOOMBERG CODE: CRIN:INSENSEX : 48,254

KEY CHANGES:

TARGET 1

Outlook intact despite weak quarter...

Coromandel International (CRIN) is one of the leading private sector fertilizer producers in the country with significant presence in South India. They are one of the leading producers of NPK and SSP grade fertilizers.

- CRIN's total revenues in Q4FY21 de-grew by 0.5% YoY to Rs.2,856cr on the back of de-growth in revenues and volumes from the fertilizer business.
- The de-growth was mainly due to the planned maintenance shutdown of fertilizer plants and inventory build-up for the kharif season.
- The crop protection business saw a 16.5% growth YoY to Rs.515cr in revenues during the quarter with new product launches contributing to revenue growth.
- CRIN received subsidy reimbursements of Rs.2,943cr from the government in Q4FY21, which will improve the working capital cycle in the long term.
- Rainfall is forecasted to be normal in the coming year which will enable further volume growth.
- We reiterate a "Buy" rating on CRIN with a target price of Rs.941 based on 16x FY23E EPS.

Fertilizer revenues decline

CRIN's total revenue de-grew by 0.5% YoY in Q4FY21 on the back of de-growth in volumes and revenue from the fertilizer business (-2.9% YoY). The decline in volumes was mainly attributed to the early annual maintenance shutdown of the fertilizer plants as well as the building up of inventory for the upcoming kharif season. The crop protection business grew by 16.5% YoY in Q4FY21 as new launches continue to gain traction. The increase in key raw material prices and higher freight rates during the quarter led to a decline in EBITDA margins (-450bps YoY) and net profits (-33.6% YoY).

Government subsidy pay-out boosts balance sheet

CRIN received subsidy reimbursements of Rs.2,943cr in Q4FY21 vs Rs.100cr in Q4FY20. The large subsidy pay-out was on the back of the announcement by the finance ministry during the union budget to allocate a further Rs.65000cr to settle outstanding fertilizer subsidy. We expect CRIN's receivables to substantially decline going forward thus improving its working capital performance in the long term as well as generation of higher free cash flow.

Capex plans to improve bottom-line

The management stated that it plans to incur a capex of Rs.500-600cr over the next 2 years across different segments. CRIN will set up a large evaporator plant in Vizag which will improve the availability of phosphoric acid, a key raw material. Once operational in FY22, the plant will enable CRIN to further reduce raw material costs and improve margins. In the crop protection business, the company looking at acquiring molecules that are going off-patent as well as incurring capex for R&D and product development.

Outlook and valuation

We expect revenue/net profit to grow at a CAGR of 9%/17% during FY20-FY23E. The management expects a normal monsoon which will aid volume growth of the fertilizer products. Despite a decline in margins in Q4FY21, margins should continue to improve in FY22, on the back of backward integration measures and price hikes of few fertilizer products. The company will also look to increase its share of revenues from higher-margin segments like crop protection and speciality nutrients through new launches and better marketing initiatives. The large subsidy pay-out from the government has eased the working capital constraints and will enable CRIN to generate higher cash flow for potential organic and inorganic opportunities. We reiterate a "Buy" rating on CRIN with a target price of Rs.941 based on 16x FY23E EPS.

	Buy
iod	Rating as r

Rating as per Mid Cap

CMP Rs.725 TARGET Rs.941 RETURN 30% 1 (Closing: 04-05-21)

RATING

12M Investment Per

		-
T A D	NINCS	
LADI		

Company Data					
Market Cap (Rs cr)	Rs.21,414				
Enterprise Value (Rs	Rs.21,076				
Outstanding Shares (cr)		29.3		
Free Float			42.4		
Dividend Yield			1.6%		
52 week high (Rs)			Rs.880		
52 week low (Rs)			Rs.564		
6m average volume (0.03				
Beta			0.2		
Face value (Rs)			Rs.1		
			-		
Shareholding (%)	Q2FY21	Q3FY21	Q4FY21		
	Q2FY21 59.6	Q3FY21 57.6	Q4FY21 57.6		
Shareholding (%)			57.6 7.7		
Shareholding (%) Promoters	59.6	57.6	57.6		
Shareholding (%) Promoters FPI's	59.6 5.9	57.6 7.0	57.6 7.7		
Shareholding (%) Promoters FPI's MFs/Institutions	59.6 5.9 19.6	57.6 7.0 19.2	57.6 7.7 20.6		
Shareholding (%) Promoters FPI's MFs/Institutions Public	59.6 5.9 19.6 14.9	57.6 7.0 19.2 16.2	57.6 7.7 20.6 14.1		
Shareholding (%) Promoters FPI's MFs/Institutions Public Total	59.6 5.9 19.6 14.9 100.0	57.6 7.0 19.2 16.2 100.0	57.6 7.7 20.6 14.1 100.0		
Shareholding (%) Promoters FPI's MFs/Institutions Public Total Price Performance	59.6 5.9 19.6 14.9 100.0 3 month	57.6 7.0 19.2 16.2 100.0 6 month	57.6 7.7 20.6 14.1 100.0 1 year		
Shareholding (%) Promoters FPI's MFs/Institutions Public Total Price Performance Absolute Return	59.6 5.9 19.6 14.9 100.0 3 month -7.3%	57.6 7.0 19.2 16.2 100.0 6 month -2.4%	57.6 7.7 20.6 14.1 100.0 1 year 27.8%		

*over or under performance to benchmark index



			-
Consolidated (cr)	FY21A	FY22E	FY23E
Sales	14,213	15,736	16,933
Growth (%)	8.2	10.7	7.6
EBITDA	2,014	2,321	2,557
EBITDA Margin(%)	14.2	14.8	15.1
PAT Adj.	1,328	1,574	1,720
Growth (%)	24.8	18.5	9.3
Adj.EPS	45.4	53.8	58.8
Growth (%)	24.8	18.5	9.3
P/E	16.1	13.6	12.4
P/B	4.2	3.3	2.7
EV/EBITDA	11.4	8.9	7.9
ROE (%)	28.0	27.2	24.0
D/E	0.0	0.0	0.0



Quarterly Financials (Consolidated)

(Rs cr)	Q4FY21	Q4FY20	YoY Growth (%)	Q3FY21	QoQ Growth (%)	FY21	FY20	YoY Growth (%)
Sales	2,856	2,869	(0.5)	3,533	(19.2)	14,213	13,136	8.2
EBITDA	261	391	(33.3)	499	(47.8)	2,014	1,731	16.4
EBITDA margins %	9.1	13.6	(450)bps	14.1	(500)bps	14.2	13.2	100bps
Depreciation	47	45	3.7	42	10.4	173	158	9.6
EBIT	214	345	(38.1)	457	(53.2)	1,735	1,337	17.1
Interest	16	43	(62.2)	21	(20.0)	106	235	(54.9)
Other Income	16	12	37.4	9	77.5	44	40	10.4
Exceptional Items	-	-	-	-	-	-	-	-
PBT	213	314	(32.1)	447	(52.3)	1,785	1,378	29.5
Tax	58	80	(28.0)	113	(49.1)	457	314	45.8
Share of profit from Associate	-0.2	0.4	-	2	-	5	-	-
Reported PAT	156	234	(33.6)	334	(33.6)	1,329	1,064	24.8
Adjustments	-	-	-	-	-	-	-	-
Adj PAT	156	234	(33.6)	334	(33.6)	1,329	1,064	24.8
No. of Shares	29	29		29	-	29	29	-
Adj EPS (Rs)	5.3	8.0	(33.6)	11.4	(33.6)	45.3	36.4	24.8

Change in Estimates

	Old esti	mates	New esti	mates	Char	ıge %
Year / Rs Cr	FY22E	FY23E	FY22E	FY23E	FY22E	FY23E
Revenue	15,425	16,533	15,736	16,933	2.0%	2.4%
EBITDA	2,337	2,480	2321	2557	-0.7%	3.1%
Margins (%)	14.3	15	14.8%	15.1%	100bps	120bps
Adj. PAT	1,523	1,671	1574	1720	3.3%	2.9%
EPS	52.1	57.1	53.8	58.8	3.3%	3.0%





Consolidated Financials

PROFIT & LOSS

Y.E March (Rs cr)	FY19A	FY20A	FY21A	FY22E	FY23E
Sales	13,225	13,136	14,213	15,736	16,933
% change	18.9	-0.7	8.2%	10.7	7.6
EBITDA	1443	1,731	2,014	2,321	2,557
% change	14.9	19.9	16.4%	15.2	10.2
Depreciation	114	158	173	207	231
EBIT	1,079	1,337	1,735	2,047	2,269
Interest	251	235	106	67	57
Other Income	37	40	44	52	56
PBT	1,093	1,378	1,785	2,098	2,324
% change	5.2	26.1	29.5%	17.6	10.8
Tax	372	314	457	525	604
Tax Rate (%)	34	23	26	25	26
Reported PAT	720	1,065	1,328	1,574	1,720
Adj.*	24	1	0	0	0
Adj. PAT	744	1,065	1,329	1,574	1,720
% change	7.7	42.9	24.8	18.5	9.3
No. of shares (cr)	25.4	25.4	25.4	25.4	25.4
Adj EPS (Rs)	25	36	45	54	59
% change	7.7	42.9	24.8	18.5	9.3
DPS (Rs)	7	8	8	8	8

BALANCE SHEET

Y.E March (Rs cr)	FY19A	FY20A	FY21A	FY22E	FY23E
Cash	132	50	692	1,434	2,051
Account Receivable	4,218	4,050	1,144	1,724	1,856
Inventories	3,241	2,697	3,085	3,749	2,827
Other Cur. Assets	706	539	696	754	789
Investments	201	211	236	261	286
Gross Fixed Assets	2,519	2,989	3,244	3,594	4094
Net Fixed Assets	1,301	1,614	1,676	1,816	2106
CWIP	176	49	140	100	100
Intangible Assets	24	23	31	28	25
Other Assets	120	458	478	479	414
Total Assets	10,574	10,148	11,737	13,214	12,338
Current Liabilities	4,106	3,727	4,066	4,024	3,769
Provisions	32	36	36	43	46
Debt Funds	2,954	1,625	2	214	229
Other Liabilities	123	444	430	406	415
Equity Capital	29	29	29	29	29
Reserves & Surplus	3,329	4,288	5323	6480	7849
Shareholder's Fund	3,358	4,318	5,352	6,510	7,878
Total Liabilities	10,574	10,148	11,737	13,214	12,338
BVPS	115	148	183	223	269

CASH FLOW

Y.E March	FY19A	FY20A	FY21A	FY22E	FY23E
Net inc. + Depn.	1,206	1,536	1,959	2,306	2,556
Non-cash adj.	264	536	138	274	288
Changes in W.C	-460	312	2,695	-211	-473
C.F. Operation	526	1,862	4,150	1,637	1,535
Capital exp.	-273	-256	-188	-453	-500
Change in inv.	-330	0	0	0	0
Other invest.CF	4	37	-1,053	-258	-156
C.F - Investment	-597	-222	-1257	-716	-653
Issue of equity	5	14	14	0	0
Issue/repay debt	232	-1357	-1624	189	24
Dividends paid	-229	-124	-528	-283	-283
Other finance.CF	-251	-240	-107	-67	-57
C.F - Finance	-244	-1,723	-2,263	-179	-266
Chg. in cash	-315	-83	630	741	617
Closing cash	132	50	692	1,434	2,051

RATIOS

Y.E March	FY19A	FY20A	FY21A	FY22E	FY23E
Profitab & Return					
EBITDA margin (%)	10.9	13.2	14.2	14.7	15.1
EBIT margin (%)	10.1	12.0	13.0	13.4	13.7
Net profit mgn.(%)	5.4	8.1	9.3	10.0	10.2
ROE (%)	23.0	27.7	28.0	27.2	24.0
ROCE (%)	21.7	24.4	30.6	33.2	29.7
W.C & Liquidity					
Receivables (days)	116	115	67	33	39
Inventory (days)	108	120	100	89	87
Payables (days)	140	143	118	120	135
Current ratio (x)	2.1	2.1	2.0	2.1	2.5
Quick ratio (x)	1.1	1.1	0.6	0.8	1.0
Turnover &Leverage					
Gross asset T.O (x)	5.3	4.8	4.6	4.7	4.4
Total asset T.O (x)	1.3	1.3	1.5	1.6	1.5
Int. covge. ratio (x)	5.3	6.7	17.4	31.5	40.9
Adj. debt/equity (x)	0.9	0.4	0.0	0.0	0.0
Valuation					
EV/Sales (x)	1.8	1.8	1.6	1.3	1.2
EV/EBITDA (x)	16.3	13.9	11.4	8.9	7.9
P/E (x)	28.7	20.1	16.1	13.6	12.4
P/BV (x)	6.4	5.0	4.2	3.3	2.7



656

821

942

837

914

941

Recommendation Summary (Last 3 years)



Invoctment Criteria

investment ci	iteria		
Ratings	Large caps	Midcaps	Small caps
Buy	Upside is above 10%	Upside is above 15%	Upside is above 20%
Accumulate	-	Upside is between 10% - 15%	Upside is between 10% - 20%
Hold	Upside is between 0% - 10%	Upside is between 0% - 10%	Upside is between 0% - 10%
Reduce/sell	Downside is more than 0%	Downside is more than 0%	Downside is more than 0%
Not rated		-	

Definition:

Buy: Acquire at Current Market Price (CMP), with the target mentioned in the research note.

Accumulate: Partial buying or to accumulate as CMP dips in the future.

Hold: Hold the stock with the expected target mentioned in the note.

Reduce: Reduce your exposure to the stock due to limited upside.

Sell: Exit from the stock

Not rated : The analyst has no investment opinion on the stock.

To satisfy regulatory requirements, we attribute 'Accumulate' as Buy and 'Reduce' as Sell.

The recommendations are based on 12 month horizon, unless otherwise specified. The investment ratings are on absolute positive/negative return basis. It is possible that due to volatile price fluctuation in the near to medium term, there could be a temporary mismatch to rating. For reasons of valuations/return/lack of clarity/event we may revisit rating at appropriate time. Please note that the stock always carries the risk of being upgraded to BUY or downgraded to a HOLD, REDUCE or SELL.

General Disclosures and Disclaimers

CERTIFICATION

I, Sheen G, author of this Report, hereby certify that all the views expressed in this research report reflect our personal views about any or all of the subject issuer or securities. This report has been prepared by the Research Team of Geojit Financial Services Limited, hereinafter referred to as Geojit.

Geojit Financial Services Limited (hereinafter Geojit), a publically listed company, is engaged in services of retail broking, depository services, portfolio management and marketing investment products including mutual funds, insurance and properties. Geojit is a SEBI registered Research Entity and as such prepares and shares research data and reports periodically with clients, investors, stake holders and general public in compliance with Securities and Exchange Board of India (Research Analysts) Regulations, 2014 and/or any other applicable directives, instructions or guidelines issued by the Regulators from time to time.

DISTRIBUTION OF REPORTS

This document is not for public distribution and has been furnished to you solely for your information and must not be reproduced or redistributed to any other person. Geojit will not treat the recipients of this report as clients by virtue of their receiving this report.

GENERAL REPRESENTATION

The research reports do not constitute an offer or solicitation for the purchase or sale of any financial instruments, inducements, promise, guarantee, warranty, or as an official confirmation of any transaction or contractual obligations of any kind. This report is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The information contained herein is from publicly available data or other sources believed to be reliable, but we do not represent that it is accurate or complete and it should not be relied on as such. We have also reviewed the research report for any untrue statements of material facts or any false or misleading information. While we endeavor to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance, or other reasons that prevent us from doing so.

RISK DISCLOSURE

Geojit and/or its Affiliates and its officers, directors and employees including the analyst/authors shall not be in any way be responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. Investors may lose his/her entire investment under certain market conditions so before acting on any advice or recommendation in these material, investors should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. This report does not take into account the specific investment objectives, financial situation/circumstances and the particular needs of any specific person who may receive this document. The user assumes the entire risk of any use made of this information. Each recipient of this report should make such investigation as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this report (including the merits and risks involved). The price, volume and income of the investments referred to in this report may fluctuate and investors may realize losses that may exceed their original capital.

FUNDAMENTAL DISCLAIMER

We have prepared this report based on information believed to be reliable. The recommendations herein are based on 12 month horizon, unless otherwise specified. The investment ratings are on absolute positive/negative return basis. It is possible that due to volatile price fluctuation in the near to medium term, there could be a temporary mismatch to rating. For reasons of valuations/return/lack of clarity/event we may revisit rating at appropriate time. The stocks always carry the risk of being upgraded to buy or downgraded to a hold, reduce or sell. The opinions expressed are subject to change but we have no obligation to tell our clients when our opinions or recommendations change. This report is non-inclusive and does not consider all the information that the recipients may consider material to investments. This report is issued by Geojit without any liability/undertaking/commitment on the part of itself or anyof its entities. We may have issued or may issue on the companies covered herein, reports, recommendations or information which is contrary to those contained in this report. The projections and forecasts described in this report should be evaluated keeping in mind the fact that these are based on estimates and assumptions and will vary from actual results over a period of time. The actual performance of the companies represented in the report may vary from those projected. These are not scientifically proven to guarantee certain intended results and hence, are not published as a warranty and do not carry any evidentiary value whatsoever. These are not to be relied on in or as contractual, legal or tax advice. Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice





JURISDICTION

The securities described herein may not be eligible for sale in all jurisdictions or to all categories of investors. The countries in which the companies mentioned in this report are organized may have restrictions on investments, voting rights or dealings in securities by nationals of other countries. Distributing/taking/sending/ dispatching/transmitting this document in certain foreign jurisdictions may be restricted by law, and persons into whose possession this document comes should inform themselves about, and observe any such restrictions. Failure to comply with this restriction may constitute a violation of any foreign jurisdiction laws. Foreign currencies denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. Investors in securities such as ADRs, the value of which are influenced by foreign currencies effectively assume currency risk.

REGULATORY DISCLOSURES:

Geojit's Associates consists of privately held companies such as Geojit Technologies Private Limited (GTPL- Software Solutions provider), Geojit Credits Private Limited (GCPL- NBFC Services provider), Geojit Investment Services Limited (GISL- Corporate Agent for Insurance products), Geojit Financial Management Services Private Limited (GFMSL) & Geojit Financial Distribution Private Limited (GFDPL), (Distributors of Insurance and MF Units). In the context of the SEBI Regulations on Research Analysts (2014), Geojit affirms that we are a SEBI registered Research Entity and in the course of our business as a stock market intermediary, we issue research reports /research analysis etc that are prepared by our Research Analysts. We also affirm and undertake that no disciplinary action has been taken against us or our Analysts in connection with our business activities.

In compliance with the above mentioned SEBI Regulations, the following additional disclosures are also provided which may be considered by the reader before making an investment decision:

1. Disclosures regarding Ownership*:

Geojit confirms that:

It/its associates have no financial interest or any other material conflict in relation to the subject company (ies) covered herein. It/its associates have no actual beneficial ownership greater than 1% in relation to the subject company (ies) covered herein.

Further, the Analyst confirms that:

He, his associates and his relatives have no financial interest in the subject company (ies) covered herein, and they have no other material conflict in the subject company.

He, his associates and his relatives have no actual/beneficial ownership greater than 1% in the subject company covered.

2. Disclosures regarding Compensation:

During the past 12 months, Geojit or its Associates:

(a) Have not received any compensation from the subject company. (b) Have not managed or co-managed public offering of securities for the subject company. (c) Have not received any compensation for investment banking or merchant banking from the subject company. However, the subject company is a client of ours, who is provided with broking services for which we charge brokerage/commission. We also has a B2B arrangement with the subject company. (d) Have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company. (e) Have not received any compensation or other benefits from the subject company or third party in connection with the research report. (f) The subject company is / was a client during twelve months preceding the date of distribution of the research report.

3. Disclosure by Geojit regarding the compensation paid to its Research Analyst:

Geojit hereby confirms that no part of the compensation paid to the persons employed by it as Research Analysts is based on any specific brokerage services or transactions pertaining to trading in securities of companies contained in the Research Reports.

4. Disclosure regarding the Research Analyst's connection with the subject company:

It is affirmed that, Sheen G, Research Analyst(s) of Geojit have not served as an officer, director or employee of the subject company

5. Disclosure regarding Market Making activity:

Neither Geojit/its Analysts have engaged in market making activities for the subject company.

Please ensure that you have read the "Risk Disclosure Documents for Capital Market and Derivatives Segments" as prescribed by the Securities and Exchange board of India.

Geojit Financial Services Ltd. (formerly known as Geojit BNP Paribas Financial Services Ltd.), Registered Office: 34/659-P, Civil Line Road, Padivattom, Kochi-682024, Kerala, India. Phone: +91 484-2901000, Website: www.geojit.com. For investor queries: customercare@geojit.com, For grievances: grievances:

Corporate Identity Number: L67120KL1994PLC008403, SEBI Stock Broker Registration No INZ000104737, Research Entity SEBI Reg No: INH200000345, Investment Adviser SEBI Reg No: INA200002817, Portfolio Manager: INP000003203, Depository Participant: IN-DP-325-2017, ARN Regn.Nos:0098, IRDA Corporate Agent (Composite) No.: CA0226